Amaranth Medical, a Mountain View, California-based medical device company, closed a $20m Series B financing.
The round was led by new investor DCP Management of Singapore, with participation from existing investors Bio*One Capital, Charter Life Sciences and Phillip Capital, as well as new investor Venstar Capital.
Led by Kamal Ramzipoor, General Manager and Chief Technical Officer, Amaranth Medical has created a novel technology platform for the development and manufacturing of fully bioresorbable scaffolds. It has research and manufacturing operations both in Singapore and at its Silicon Valley headquarters.
The company intends to use the funds to develop the upcoming CE Mark clinical trial of FORTITUDE™, a bioresorbable scaffold for use in treating coronary artery disease.